CL2022003007A1 - Compuestos de azalactama como inhibidores de hpk1 - Google Patents

Compuestos de azalactama como inhibidores de hpk1

Info

Publication number
CL2022003007A1
CL2022003007A1 CL2022003007A CL2022003007A CL2022003007A1 CL 2022003007 A1 CL2022003007 A1 CL 2022003007A1 CL 2022003007 A CL2022003007 A CL 2022003007A CL 2022003007 A CL2022003007 A CL 2022003007A CL 2022003007 A1 CL2022003007 A1 CL 2022003007A1
Authority
CL
Chile
Prior art keywords
compounds
azalactam
hpk1 inhibitors
salts
hpk1
Prior art date
Application number
CL2022003007A
Other languages
English (en)
Inventor
Bryce Tuttle Jamison
BARBER Joyann
Cho-Schultz Sujin
L Del Bel Matthew
Anne Gallego Rebecca
He Mingying
Jalaie Mehran
Steven Kania Robert
Ann Mctigue Michele
Krishnan Nair Sajiv
Dechert Schmitt Anne-Marie
Zhou Dahui
Zhou Ru
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2022003007A1 publication Critical patent/CL2022003007A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere a compuestos de la Fórmula general I y sales farmacéuticamente aceptables de los mismos, en los que R1, R2, R3a, R3b y R4 son como se definen en el presente documento, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos de uso de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer.
CL2022003007A 2020-05-01 2022-10-28 Compuestos de azalactama como inhibidores de hpk1 CL2022003007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063018689P 2020-05-01 2020-05-01

Publications (1)

Publication Number Publication Date
CL2022003007A1 true CL2022003007A1 (es) 2023-06-16

Family

ID=75769663

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003007A CL2022003007A1 (es) 2020-05-01 2022-10-28 Compuestos de azalactama como inhibidores de hpk1

Country Status (18)

Country Link
US (1) US11684616B2 (es)
EP (1) EP4143186A1 (es)
JP (1) JP7303948B2 (es)
KR (1) KR20230003128A (es)
CN (1) CN115698004A (es)
AR (1) AR121985A1 (es)
AU (1) AU2021265578B2 (es)
CA (1) CA3181415A1 (es)
CL (1) CL2022003007A1 (es)
CO (1) CO2022015448A2 (es)
CR (1) CR20220548A (es)
EC (1) ECSP22084264A (es)
IL (1) IL297838A (es)
MX (1) MX2022013401A (es)
PE (1) PE20230323A1 (es)
TW (1) TWI806043B (es)
UY (1) UY39193A (es)
WO (1) WO2021220185A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TW202328152A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 氮雜內醯胺化合物之晶型
WO2023057882A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CA3041033A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
CN111094250B (zh) 2017-03-03 2022-11-04 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
TW201908306A (zh) * 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
KR20220105631A (ko) 2019-09-13 2022-07-27 님버스 새턴 인코포레이티드 Hpk1 길항제 및 이의 용도
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors

Also Published As

Publication number Publication date
KR20230003128A (ko) 2023-01-05
TW202202496A (zh) 2022-01-16
CN115698004A (zh) 2023-02-03
CR20220548A (es) 2022-12-12
AR121985A1 (es) 2022-07-27
AU2021265578B2 (en) 2024-03-28
AU2021265578A1 (en) 2022-11-10
PE20230323A1 (es) 2023-02-22
UY39193A (es) 2021-11-30
JP7303948B2 (ja) 2023-07-05
JP2023515900A (ja) 2023-04-14
IL297838A (en) 2023-01-01
US20220401424A1 (en) 2022-12-22
CO2022015448A2 (es) 2022-11-18
EP4143186A1 (en) 2023-03-08
CA3181415A1 (en) 2021-11-04
MX2022013401A (es) 2022-11-14
WO2021220185A1 (en) 2021-11-04
ECSP22084264A (es) 2022-11-30
TWI806043B (zh) 2023-06-21
US11684616B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
CO2022015448A2 (es) Compuestos de azalactama como inhibidores de hpk1
UY38553A (es) Inhibidores de cdk2
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
UY37900A (es) Nuevos derivados de rapamicina
UY38196A (es) Inhibidores de cinasa dependientes de ciclina
NI201400102A (es) Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
UY33071A (es) Nuevos compuestos tricíclicos
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
ECSP14013215A (es) Compuestos novedosos
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
DOP2023000281A (es) Inhibidores de mutación de her2
UY39517A (es) Inhibidores de la btk
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
UY39303A (es) Inhibidores de mutación her2
AR122805A1 (es) Inhibidores de mutación her2
CU20140107A7 (es) Derivados macrocíclicos para el tratamiento de enfermedades
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
UY33816A (es) ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?.